Welcome to the e-CCO Library!

DOP60: Self-reported treatment effectiveness for Crohn's Disease using a novel crowdsourcing web-based platform
Year: 2022
Source: ECCO'22
Authors: Engel, T.(1);Dotan, E.(2);Ben-Horin, S.(1);Kopylov, U.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP60: Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study data
Year: 2021
Source: ECCO'21 Virtual
Authors: Mantzaris, G.(1);Yarur, A.(2);Wang, S.(3);Adsul, S.(4);Kamble, P.(4);Luo, M.(3);Guerin, A.(5);Billmyer, E.(5);Nguyen, H.(5);Bressler, B.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Pavlidis*1, A. Tsakmaki1, U. Niazi2, J. Digby-Bell1, G. Lombardi1, B. Hayee3, G. Bewick1, N. Powell1

Created: Friday, 22 February 2019, 9:41 AM
DOP60: Vedolizumab treatment persistence and safety in an extended access program (XAP)
Year: 2020
Source: ECCO'20 Vienna
Authors: Silvio Danese
Created: Tuesday, 23 June 2020, 5:40 PM
DOP60: Vedolizumab treatment persistence and safety in an extended access program (XAP)
Year: 2020
Source: ECCO'20 Vienna
Authors: Silvio Danese
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G.R. Lichtenstein1, E.V. Loftus Jr2, S.C. Wei3, A.O. Damião4, D. Judd5, N. Lawendy5, G. Chan5, H. Zhang5, W. Wang5, A.J. Thorpe5, S. Bloom6

Created: Thursday, 30 January 2020, 10:12 AM
DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Worley*1,2, A. Almoudaris1,2, P. Bassett3,4, J. Segal1,2, A. Akbar2,4, P. Aylin5, O. Faiz1,2

Created: Friday, 22 February 2019, 9:41 AM
DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Jonathan Segal
Created: Tuesday, 28 May 2019, 3:32 PM
Epidemiology, Natural history, Ulcerative colitis, Colectomy, Anti-TNF agents, Infliximab, Acute Severe Colitis
Files: 1
DOP61: Development and validation of novel models in prediction of intravenous corticosteroids resistance in patients with Acute Severe Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Yu, S.(1);Li, H.(2);Li, Y.(1);Xu, H.(1);Tan, B.(1);Tian, B.(1);Dai, Y.(1);Tian, F.(2);Qian, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP61: Ethnic disparities in the management of Inflammatory Bowel Disease in Israel and impact on outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dan Turner
Created: Friday, 14 July 2023, 2:22 PM
DOP61: Ethnic disparities in the management of Inflammatory Bowel Disease in Israel and impact on outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Boaz, E.(1)*;Ledder, O.(2);Dagan, A.(1);Lujan, R.(2);Koslowsky, B.(3);Friss, C.(2);Greenfeld, S.(4);Kariv, R.(4);Loewenberg Weisband , Y.(5);Lederman, N.(6);Matz, E.(7);Dotan, I.(8);Yellinek, S.(1);Turner, D.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP61: Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study
Year: 2021
Source: ECCO'21 Virtual
Authors: Sandborn, W.J.(1);Dubinsky, M.C.(2);Torres, J.(3);Vermeire, S.(4);Kotze, P.G.(5);Su, C.(6);Lawendy, N.(6);Paulissen, J.(7);Mundayat, R.(7);Gardiner, S.(7);Kulisek, N.(6);Modesto, I.(7);D’Haens, G.R.(8)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP61: Up-regulated Gremlin 1 in fibroblasts from Crohn’s Disease fibrotic strictures: A potential therapeutic target
Year: 2024
Source: ECCO'24 Stockholm
Authors: Santacroce, Giovanni
Created: Tuesday, 30 April 2024, 5:03 PM
DOP62 Morbidity after primary ileocecal resection for Crohn’s disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Rottoli1, M. Tanzanu1, G. Vago1, A. Belvedere1, D. Parlanti1, P. Pezzuto1, S. Bosi1, F. Caputo1, F. Rizzello2, P. Gionchetti2, G. Poggioli1

Created: Thursday, 30 January 2020, 10:12 AM
DOP62: A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Reinisch*1, B. I. Jang2, V. Borzan3, A. Lahat4,5, A. Pukitis6, M. Osipenko7, Y. Mostovoy8, S. Schreiber9, S. Ben-Horin10, S. J. Lee11, J. H. Suh11, S. G. Lee11, J. H. Lee11, B. D. Ye12

Created: Friday, 22 February 2019, 9:41 AM
DOP62: A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 1-Year Result from a Phase I Open-label Randomised Controlled Trial in Patients with Active Crohn’s Disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Walter Reinisch
Created: Tuesday, 28 May 2019, 3:32 PM
Outcome measures, Mucosal healing, Infliximab, Pharmacokinetics
Files: 1
DOP62: Efficacy of biologic drugs in short-duration versus long-duration Inflammatory Bowel Disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials
Year: 2022
Source: ECCO'22
Authors: Ben-Horin, S.(1,2);Novack, L.(3);Mao, R.(2);Guo, J.(2);Zhao, Y.(2);Sergienko, R.(3);Zhang, J.(2);Kobayashi, K.(4);Hibi, T.(4);Chowers, Y.(5);Peyrin-Biroulet, L.(6);Colombel, J.F.C.(7);Kaplan, G.G.K.(8);Chen, M.H.(2);
Created: Friday, 11 February 2022, 3:52 PM